CJC-1295 (No DAC) Reconstitution Chart (Every Vial Size)

Overview of CJC-1295 (No DAC) Chemical Structure and Reconstitution Science

CJC-1295 (No DAC), also classified as Modified GRF 1-29, is a synthetic 29-amino acid peptide derivative representing the functional catalytic domain of endogenous Growth Hormone-Releasing Hormone (GHRH). In laboratory settings, this compound is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. The removal of the Drug Affinity Complex (DAC) alters the pharmacokinetic profile compared to DAC-bound variants, resulting in a shorter biological half-life that closely mimics physiological GHRH pulsatility when evaluated in preclinical models.

To achieve accurate experimental outputs, researchers must convert the solid lyophilized cake of CJC-1295 (No DAC) into a stable liquid solution of known concentration. Reconstitution requires non-pyrogenic sterile diluents—typically Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl)—to dissolve the peptide mass without compromising its tertiary structure or peptide bond stability. Proper dilution parameters are essential for preventing concentration variance across experimental trials.

Mathematical Reconstitution Formula and Volumetric Equations

Calculating the final liquid concentration of a reconstituted research peptide relies on straightforward volumetric mass equations. Laboratory technicians can determine the resulting concentration in milligrams per milliliter (mg/mL) or micrograms per 0.1 milliliter (mcg/0.1mL, corresponding to 10 units on a standard 100-unit U-100 volumetric laboratory syringe) using the following baseline formulas:

**Concentration Formula:** `Concentration (mg/mL) = Total Peptide Mass (mg) / Diluent Volume (mL)`

**Microgram per 0.1 mL Formula:** `Concentration per 0.1 mL (mcg) = (Total Peptide Mass (mg) * 1000) / (Diluent Volume (mL) * 10)`

For complex calculations involving custom diluent volumes or non-standard vial masses, researchers can utilize the online interactive reconstitution calculator tool to verify volumetric accuracy before liquid preparation.

Master Reconstitution Chart: 2mg Lyophilized Vial Matrix

The 2mg vial quantity is standard for small-scale preclinical studies and localized in vitro screening assays. The table below illustrates the resulting concentrations when reconstituting a 2mg CJC-1295 (No DAC) vial with various volumes of sterile diluent:

| Diluent Volume Added | Final Concentration (mg/mL) | Micrograms per 0.05 mL (5 Units) | Micrograms per 0.10 mL (10 Units) | Micrograms per 0.20 mL (20 Units) | | :--- | :--- | :--- | :--- | :--- | | 1.0 mL | 2.00 mg/mL | 100 mcg | 200 mcg | 400 mcg | | 1.5 mL | 1.33 mg/mL | 66.7 mcg | 133.3 mcg | 266.7 mcg | | 2.0 mL | 1.00 mg/mL | 50 mcg | 100 mcg | 200 mcg | | 2.5 mL | 0.80 mg/mL | 40 mcg | 80 mcg | 160 mcg | | 3.0 mL | 0.67 mg/mL | 33.3 mcg | 66.7 mcg | 133.3 mcg |

Choosing the appropriate volume depends on the required working dilution for the test system. A 2.0 mL addition to a 2mg vial yields a convenient 1.0 mg/mL concentration (100 mcg per 0.1 mL), simplifying volumetric measurements during assay execution.

Master Reconstitution Chart: 5mg Lyophilized Vial Matrix

For multi-subject animal models or high-throughput cell culture protocols, 5mg vials provide greater working volume. The matrix below outlines the exact concentration dynamics for a 5mg CJC-1295 (No DAC) vial:

| Diluent Volume Added | Final Concentration (mg/mL) | Micrograms per 0.05 mL (5 Units) | Micrograms per 0.10 mL (10 Units) | Micrograms per 0.20 mL (20 Units) | | :--- | :--- | :--- | :--- | :--- | | 1.0 mL | 5.00 mg/mL | 250 mcg | 500 mcg | 1000 mcg | | 2.0 mL | 2.50 mg/mL | 125 mcg | 250 mcg | 500 mcg | | 2.5 mL | 2.00 mg/mL | 100 mcg | 200 mcg | 400 mcg | | 3.0 mL | 1.67 mg/mL | 83.3 mcg | 166.7 mcg | 333.3 mcg | | 5.0 mL | 1.00 mg/mL | 50 mcg | 100 mcg | 200 mcg |

Higher diluent volumes, such as 2.5 mL or 5.0 mL, reduce concentration density, which can minimize volumetric pipetting error when working with minute aliquot volumes in preclinical research applications.

Master Reconstitution Chart: 10mg Lyophilized Vial Matrix

Bulk laboratory research requiring high total mass often utilizes 10mg vials. To review inventory across all available formats, laboratories can browse our catalog of all peptides. Below are the concentration measurements for 10mg CJC-1295 (No DAC) reconstitutions:

| Diluent Volume Added | Final Concentration (mg/mL) | Micrograms per 0.05 mL (5 Units) | Micrograms per 0.10 mL (10 Units) | Micrograms per 0.20 mL (20 Units) | | :--- | :--- | :--- | :--- | :--- | | 2.0 mL | 5.00 mg/mL | 250 mcg | 500 mcg | 1000 mcg | | 3.0 mL | 3.33 mg/mL | 166.7 mcg | 333.3 mcg | 666.7 mcg | | 4.0 mL | 2.50 mg/mL | 125 mcg | 250 mcg | 500 mcg | | 5.0 mL | 2.00 mg/mL | 100 mcg | 200 mcg | 400 mcg | | 10.0 mL | 1.00 mg/mL | 50 mcg | 100 mcg | 200 mcg |

Ensure that the selected vial capacity can accommodate larger diluent volumes (e.g., 5.0 mL or 10.0 mL) prior to liquid introduction to avoid overfilling the container head space.

Worked Calculation Examples for Laboratory Assays

**Worked Example 1:** A laboratory technician needs to prepare a 2mg vial of CJC-1295 (No DAC) to achieve a target working concentration of 100 mcg per 0.1 mL (10 units). Applying the formula: `Diluent Volume = (Total Mass in mcg) / (Target mcg per 0.1 mL * 10)`. Substituting values: `Diluent Volume = 2000 mcg / (100 mcg * 10) = 2.0 mL`. Adding exactly 2.0 mL of Bacteriostatic Water to the 2mg lyophilisate provides the precise target concentration.

**Worked Example 2:** An investigator utilizing a 5mg vial requires a higher working concentration of 250 mcg per 0.1 mL for an in vivo rodent study. Applying the equation: `Diluent Volume = 5000 mcg / (250 mcg * 10) = 2.0 mL`. Injecting 2.0 mL of sterile diluent into the 5mg vial yields 2.5 mg/mL, delivering exactly 250 mcg in every 0.1 mL aliquot.

Aseptic Reconstitution Protocol for Laboratory Preparation

Reconstitution must take place within a certified ISO Class 5 laminar flow hood or cleanroom environment to prevent microbial contamination or degradation of the research peptide. Follow this standardized protocol:

1. **Sanitization:** Swab the rubber septum of the CJC-1295 (No DAC) vial and the diluent vial with 70% isopropyl alcohol. Allow to air-dry completely. 2. **Pressure Equalization:** Draw an air volume equal to the planned diluent volume into a sterile syringe before inserting into the diluent vial to maintain vial pressure equilibrium. 3. **Diluent Extraction:** Aspirate the exact volume of diluent (e.g., Bacteriostatic Water) required according to the target concentration chart. 4. **Reagent Transfer:** Insert the needle into the CJC-1295 (No DAC) vial at a 45-degree angle. Direct the diluent stream against the glass wall of the vial rather than shooting directly onto the lyophilized cake. This prevents mechanical shearing of the peptide chains. 5. **Solubilization:** Allow the diluent to naturally saturate the powder cake. Gently roll and swirl the vial between your palms until the powder is fully dissolved. **Never shake the vial**, as vigorous agitation causes foaming and structural denaturation of the protein.

Comparative Analysis: Secretagogue Profiles and Reconstitution Dynamics

In GHRH and GH secretagogue research, CJC-1295 (No DAC) is frequently compared against related synthetic analogs to evaluate receptor affinity, binding kinetics, and half-life variations. For example, comparing CJC-1295 (No DAC) with CJC-1295 DAC highlights how the presence of the Drug Affinity Complex extends plasma binding via serum albumin, altering the reconstitution frequency required for long-term preclinical trials.

Similarly, researchers evaluating GHRH analogs often compare Modified GRF 1-29 against compounds like Sermorelin or combine GHRH pathways with ghrelin receptor agonists such as Ipamorelin. While CJC-1295 (No DAC) acts directly on GHRH receptors, ghrelin mimetics target the Growth Hormone Secretagogue Receptor (GHSR-1a). Understanding the distinct mass-to-volume requirements of each peptide ensures uniform trial conditions across multi-agent secretagogue studies.

Storage, Handling, and Degradation Mitigation Protocols

Lyophilized CJC-1295 (No DAC) powder remains stable when stored in a temperature-controlled freezer at -20°C to -80°C, protected from light. Under these conditions, the un-reconstituted peptide maintains chemical integrity for extended periods as documented on its batch analytical documentation.

Once reconstituted with preserved diluent (Bacteriostatic Water), liquid solutions should be refrigerated at 2°C to 8°C and evaluated within 28 days. Avoid subjecting reconstituted liquid solutions to repeated freeze-thaw cycles, which induce physical stress and aggregation of the peptide molecules. Detailed handling protocols for institutional researchers are outlined in our PX1 Research Library.

Analytical Quality Verification and Quality Control Assurance

Experimental integrity depends entirely on the chemical purity and accurate mass labeling of research compounds. PX1 Research subjects every production lot of CJC-1295 (No DAC) to rigorous quality control protocols in an ISO 17025 accredited laboratory facility. Each batch undergoes High-Performance Liquid Chromatography (HPLC) to confirm peptide purity (>= 98%) and Mass Spectrometry (MS) to verify exact molecular weight.

Furthermore, compounds are screened for bacterial endotoxin levels using Limulus Amebocyte Lysate (LAL) testing to ensure compliance with stringent preclinical laboratory standards. Researchers can access lot-specific analytical documentation via our Certificate of Analysis (COA) portal. Institutional facilities purchasing bulk quantities for ongoing studies can establish direct procurement channels through our wholesale lab portal.